While FMO3 inhibitors reduce TMAO levels, they risk adverse effects like hepatic inflammation, and individuals with FMO3 gene defects may develop trimethylaminuria (fish odour syndrome). This evidence concerns the gene FMO3 and trimethylaminuria.